- Home
- / Orchard Therapeutics
Orchard Therapeutics
Revenue
$22.7 M
FY, 2022
Orchard Therapeutics Summary
Company Summary
- Overview
- Orchard Therapeutics is a biotechnology company that develops transformative ex vivo autologous hematopoietic stem cell gene therapy. It also provides adenosine deaminase severe combined immunodeficiency, mucopolysaccharidosis type IIIA, and ex vivo lentiviral gene therapy programs.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2015
- HQ
- London, GB | view all locations
- Website
- https://www.orchard-tx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
John Cerio, Chief Human Resource Officer
Nicoletta Loggia, Chief Technical Officer
Frank Thomas, President, Chief Operating Officer
LocationsView all
5 locations detected
London, England HQ
United Kingdom
108 Cannon St
Boston, MA
United States
101 Seaport Blvd 7th floor
Boston, MA
United States
2 Seaport Ln 8th floor
Foster City, CA
United States
1118 Chess Dr
Menlo Park, CA
United States
1360 O'Brien Dr
Orchard Therapeutics Financials
Summary Financials
- Revenue (Q3, 2023)
- $6.3M
- Gross profit (Q3, 2023)
- $4.6M
- Net income (Q3, 2023)
- ($35.3M)
- Cash (Q3, 2023)
- $23.5M
- EBIT (Q3, 2023)
- ($21.6M)